Share Name Share Symbol Market Type Share ISIN Share Description
Nmt Group LSE:NMT London Ordinary Share GB00B030GD19 ORD 4
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 12.89p 0.00p 0.00p - - - 0 06:37:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services - - - - 0.00

Nmt Group (NMT) Latest News

Real-Time news about Nmt Group (London Stock Exchange): 0 recent articles
More Nmt Group News
Nmt Group Takeover Rumours

Nmt Group (NMT) Share Charts

1 Year Nmt Group Chart

1 Year Nmt Group Chart

1 Month Nmt Group Chart

1 Month Nmt Group Chart

Intraday Nmt Group Chart

Intraday Nmt Group Chart

Nmt Group (NMT) Discussions and Chat

Nmt Group Forums and Chat

Date Time Title Posts
10/7/200713:13NMT. 'Safer at the Sharp End'.7,582
29/11/200616:58NMT.....Good news soon?3
14/4/200620:46Come over to CMS Webview to recover your Losses20
07/9/200510:59NMT - Shares = 0.55p, Net Cash = 0.8p30

Add a New Thread

Nmt Group (NMT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Nmt Group trades in real-time

Nmt Group (NMT) Top Chat Posts

25october1969: Price post acquisition will as usual, in the first instance, be dictated by number of buyers and sellers, eg if those who exchange NMT shares for Volvere want to sell, then Volvere price will fall or at least not rise. I do not know if Volvere have any interest in their share price rising in the short term so do not know is they will use PR to highlight the 25%+ increase in NAV. If they do and have firm plans for use of the NMT cash which interest the market and existing businesses are moving into profit, then who knows we may get a move upwards Interesting that post acquisition, Merrill Lynch have 3.4%%, United Gulf Bank 4.8% and JP Morgan 6%, though possibily one of them has been selling in the market. Would hope having institutional shareholders on board might generate some city interest, who knows With respect to the small shareholders, bear in mind that we could have a scenario where Volvere get less than 90% and say stuff it, lets just delist NMT and leave the small shareholders with shares in NMT!
25october1969: Bill My philosophy nowadays is that you cannot have all your eggs in one basket with the small caps, have to spread the risk in the hope that one is a multi-bagger, and the others tick along but expact one to fall drastically. So with that in mind four shares I would mention are SAL, ELG MED and AOR. AOR is already a multi bagger for me and has risen a further 20% in the last few weeks so have to be very confident to buy at current level. I have not sold any as I see potential for it to go much further ELG is as far as I am aware an undiscovered share. There is a ADVFN Board but very few posts. They incorporate keyboards etc into fabrics so that if you have an IPod the controls are on your sleeve. Sounds a bit wierd and they are making big losses but do a google news search and see the recent contracts they have won. It sounds the type of company that could be ramped to hell so please do not take this as a ramp SAL is another undiscovered one. Very little comment on it. The are effectively brokers for advertising in shopping malls. Does not sound very exciting but seem to be the dominant player and are expanding overseas. Making a profit and paying a dividend if my memory serves me corectly MED is one where I have received a stuffing just as big as the NMT one. When the share price was in the 30/40s the board announced a placing at 20p. Price collapsed to 25p and they would not let me take part in the placing so I have been dilluted to hell as new shares of around 60% issued. There has been other bad news along the way as share price tumbled from 150 and numerous management changes. Price now 28p and placing taken up by institution who are sitting on 40% profit. I still hold and not brave enough to buy more, they are using placing proceeds to construct manufacturing facility in Germany, they make polymer organic light emitting diode (P-OLED) based microdisplays and are very good at it, they are not so good at taking the product to market. I hold all 4. In big profit in 1, small profit in 2 and big losses in the other so have a look and make up your own mind. All are fairly illiquid so timing of buying is important as price can move rapidly on small purchases/sales
waldron: Volvere agrees to buy NMT Group for 5.3 mln stg in shares LONDON (AFX) - Volvere PLC said it has agreed to buy the whole of investing company NMT Group PLC for 5.3 mln stg in shares. The company said it is offering NMT shareholders 1 new Volvere share for every three NMT shares. Based on Volvere's closing price yesterday of 182.5 pence per share, this values each NMT share at 60.8 pence and the entire company at 5.3 mln stg. Volvere, who already hold a 29.9 pct stake in NMT, said this represents around a 20.5 pct premium on NMT's closing share price yesterday of 50.5 pence. It said it has already had an undertaking to accept the offer from Wood Hall Securities who hold around 16 pct of NMT shares. rar
pc4900074200: How's this Bill? We are coming close to the start of the second act [year] of the pantomime being performed by our own 'Wolf's in Sheep Clothing'. Last year instead of the call of 'He's behind you'. We had the promising sound of 'Shareholder Value'. Remaining shareholders can all see where that has taken us? Any hope of recovery to NMT as a pharmaceuticals company was removed within a short period of time. The 'Letter of Intent', became just a letter to be disregarded to the waste bin. ZIM's pending offer fell to the wayside. We were then told that NMT was to become an investment company. The only investment that can be seen here in the months that followed are the returns that some directors are getting for their own investment in this company. We do have one game being played-out here and that is a game of yo-yo? 15% of the company has been sold then bought back by the majority shareholder in this company, who just happen to be firmly sitting on the board of director's, to be used as a battering ram to force through resolutions at the AGM. Detrimental, to the majority. Beneficial, to the few. 'We will vote ourselves back onto the board'. 'We will pass a resolution that says that we will be able to 'buy-back' up to 45% of shares in the company, enabling us to have a larger majority stake-holding' without spending any of our own money'. What a great idea! Don't invest in any thing other than our own Company for as long as we can get away with it. All legal, it must be, as they are implementing it. The share price stagnates. Small shareholders sell. NMT buys up the shares. I will not bore you with the buy / sold figures [ADVFN's] that I have totalled, but there are already 10%+ of shares sitting with the market makers waiting to be snapped-up. All this and NMT have not made any investments on behalf of their shareholders. Ethical? Well that's another story! Any smoke or mirror's? Not any in sight. I wonder what this years rallying call will be? They have used up the 'Shareholder Value' one. Any offers? pc
waldron: Sun 5 Mar 2006 Lander rejects calls to return £5m NMT cash DOUGLAS FRIEDLI JONATHAN Lander, the investor activist who took control of former syringe maker NMT last year, has rejected calls for £5m to be returned to shareholders, and insists he will publish a strategy for the failed business within weeks. Peter Gyllenhammar, a rival activist who has built up a stake of almost 15% in NMT, last week called for most of the Livingston company's £6m cash pile to be returned to shareholders. He also accused Lander, his brother Nick and fellow director Lord Kalms of being "unethical" for setting up a potentially lucrative management incentive scheme at NMT. Speaking to Scotland on Sunday, Lander said NMT's 6,500 shareholders would benefit more if the company's cash pile was reinvested. Most investors have seen the value of their investments collapse since NMT was the darling of the Scottish technology sector in the late 1990s. He said: "If we do [return cash] the only person that will make any money is Peter Gyllenhammar. "I think most people want to make some money back. [Gyllenhammar] has only been on the shareholders' register for a few months. "I invest in technology companies and growth companies. We are trying to get some value out of NMT's assets." Lander said he had drawn up a strategy for investing NMT's cash pile, which would be sent to shareholders in the next few weeks. "There are just a few people looking at it now," he said. Lander defended the fee structure which transfers money from NMT to Volvere, which is run by the Landers and Kalms. He said: "Gyllenhammar calls it unethical, but he means it is disadvantageous for him." "The fee is £5,000 a month per person, which puts me on £60,000 a year, which is a lot less than I get from other businesses. For me, NMT is a full-time job at the moment." In addition to that £15,000 monthly fee for three directors, Volvere is entitled to a payment proportionate to any rise in NMT's share price, and further cash if the Landers and Kalms are removed from the board. The Landers' supporters say the fee structure is necessary to allow them to focus on running the business and reduce the danger that they will be removed suddenly by antagonistic shareholders. However, Gyllenhammar rejected Lander's plan to invest NMT's cash pile. He said: "The only thing of interest is what I can do with the 65p per share, or whatever it is, that I am entitled to by my NMT share. "Do I want the Landers to manage that for a horrendous fee structure, or do I want the money out of the company to invest however I want? "They are putting the cart before the horse by asking investors to approve the investment plan after they have approved themselves an expensive contract." Gyllenhammar was initially positive about Volvere, but turned opponent when the company announced its fee structure the day after he raised his stake to 14.6%. He could combine with private shareholders to call an extraordinary general meeting to oppose the Landers, but said the expense would prevent him from doing so. This article: Last updated: 05-Mar-06 00:32 GMT
25october1969: Scotland on Sunday 26th Feb 2006 NMT directors' rewards 'unethical' PETER Gyllenhammar, the activist investor, has attacked the directors of cash shell company NMT, chaired by former Dixons boss Lord Kalms, as "unethical" and demanded that the former syringe developer return £5m to its shareholders. Gyllenhammar, who holds just under 15% of NMT, was left fuming after the Livingston company's board approved a fee system which will reward Volvere, a company which shares three directors with NMT. The reward system was announced the day after Gyllenhammar spent around £500,000 to raise his stake in NMT to 14.6%. Speaking from his base in Sweden, Gyllenhammar said: "This is totally unacceptable. If Volvere had come to me and asked to manage my money, I would have said no. It is not ethical conduct because 70% of shareholders do not have a say." Gyllenhammar said he had confronted NMT directors Jonathan and Nicholas Lander about the fee structure, which he said could net them millions, but had not received an adequate response. He said: "I think the best thing would be to cancel this agreement and hand the shareholders all the cash, allowing a small portion, say 10%, to stay in the company to be a vehicle." The Landers and former Dixons chairman Lord Kalms of Edgware are directors of Volvere, an investor activist company based in London. Lord Kalms' son, Richard, is also a director of Volvere. The three were elected to the board in place of the previous management team after Volvere took a 26% stake in the company and called an extraordinary general meeting. NMT, the former darling of Scotland's medical technology sector, has around £6m in cash left over from years of fundraising and restructuring. Gyllenhammar said the new management fee structure should have been put to shareholders. The precise terms of the agreement have left some investors scratching their heads. NMT will pay Volvere a monthly fee of 0.25% of its net assets, or around £15,000. Volvere is also entitled to a performance fee equal to 20% of any increase in the company's share price. If NMT terminates the agreement, Volvere is entitled to 6% of the company's net assets, or around £360,000, plus another unspecified payment based on "the value of an option using the Black Scholes model". Gyllenhammar said this termination clause would make it expensive for shareholders to follow the example set by the Landers and Kalms by calling an extraordinary general meeting to take control of the company. He said: "I don't know what to do. This is a complete scandal. If I call for an EGM, there will be significant costs." Volvere argues that the new fee structure is less expensive for NMT than the previous model. Under that deal, Volvere was entitled to £60,000 per month plus VAT for every month that NMT was subject to a takeover approach. That structure, introduced on November 26, came to an end on February 9 - two weeks after NMT ended takeover discussions with Zi Medical. In theory, that means that NMT will have to pay Volvere £140,000 including VAT for the two months to January 25. Shareholders have raised questions over the fact that non-executive directors George Wardale and Lex Gold were said by NMT to have consulted the company's adviser, Shore Capital, and approved the fees agreement. Wardale joined the company just hours before the fee structure was announced. NMT's shares closed at 57.5p on Friday, down from a peak of 62.5p when the new management fee structure was announced on February 10
pc4900074200: From Volvere's Intrim report issued this morning. Holding in NMT Group PLC Starting in October 2004 we accumulated a holding of 2,269,024 ordinary shares of #4 each in NMT Group PLC ("NMT") representing 26.04% of the total issued ordinary share capital of that company for an aggregate cash consideration of #1.47m. At the end of the period the investment in NMT was #0.39m (2 July 2004: nil). NMT is a licensing and development company for safety needle-based medical devices. For the six months ending 30 June 2005 NMT's interim results showed a loss before tax of #0.5m on sales of #nil. At that date NMT's net assets amounted to #6.76m, of which cash represented #6.51m. In view of NMT's poor financial performance, Volvere requisitioned an Extraordinary General Meeting of NMT in order to remove that company's board and replace it with executives from Volvere. On 14 September 2005, NMT shareholders voted in support of Volvere's resolutions and your Chairman, Chief Executive and Chief Operating Officer were duly elected to the board of NMT. Since that date Volvere re-financed part of its holding by disposing of 1,306,600 shares in NMT and entering into a long Contract for Difference ("CFD") over the shares sold. The CFD provides us with an economic interest in the share price of the shares sold whilst freeing up cash for other investments. Following the sale Volvere holds 962,424 shares, or 11.05 pct of NMT's issued share capital but with an economic interest in 2,269,024 (26.04%). At the average price at which the Company acquired its shares (including the shares subject to the CFD) we consider the shareholding in NMT to represent an attractive investment opportunity. We are working hard to maximise the value of this investment and will report on our progress in due course. pc
pc4900074200: The Letter. THIS LETTER IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in doubt about the action you should take regarding this letter, you are recommended to immediately consult your stockbroker, bank manager, solicitor, accountant or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000. This document is not an offer or invitation to subscribe for or purchase securities. NMT Group PLC (Company number SC170841) YOUR VOTE COUNTS Whether or not you have already voted on a white proxy card for the EGM convened for 11.00 a.m. on 14 September 2005 Sign and return your BLUE proxy card to: Remove directors who are being paid by YOU to run a company with ZERO sales Appoint directors nominated by Volvere plc, whose interests are clearly aligned with yours DO NOT DELAY - VOTE NOW If your shares are held by a nominee, please instruct the nominee to sign and return the blue proxy card as soon as possible to Capita Registrars, Proxy Department, PO Box 25, Beckenham, Kent BR3 4BR, but in any event so as to be received by 9.00 a.m. on 12 September 2005. All blue proxy cards received by 9.00 a.m. on 12 September 2005 will be filed with NMT Group PLC's registrars by the deadline of 11.00 a.m. on 12 September 2005. By completing and returning the blue proxy card, shareholders are appointing a proxy to vote in favour of proposals to remove the existing Board and to appoint in their place the three directors proposed by Volvere plc. The completion and return of the proxy card will not prevent you from attending and voting in person at the EGM if you so wish. Volvere plc (incorporated in England under the Companies Act 1985 with registered number 04478674) Directors Registered office Lord Kalms of Edgware 9-11 Grosvenor Gardens London SW1W0BD Jonathan Lander Nicholas Lander Richard Kalms Neil Ashley Daviv Buchler To the Shareholders of NMT Group PLC 31 August 2005 Dear Fellow Shareholder, TIME FOR CHANGE NMT Group PLC ("NMT" and "the Company") has, since inception, lost more than £69 million'. For the last 18 month period2, the Company has reported ZERO sales. Volvere plc ("Volvere") believes that the current Board has failed to deliver concrete results from the Company's technology, but has instead made upbeat statements since as far back as 2003. Some examples of such statements include: "Licensing discussions with regard to 2nd Generation technology are progressing with several parties demonstrating commercial interest." 6 May 2003 - Trading Update "We continue to believe that our intellectual property platform remains strong, and are in discussions with several companies on the commercialisation of our technologv." 16 January 2004 - Restructuring Update " is clear that specific opportunities do exist for the Group's products, particularly for patient self administration and pre-fill needle units for pharmaceutical companies. The Board continues to believe that the Group's intellectual property will allow it to gain a share of these specialised market segments." 4 March 2004 - Preliminary Announcement of Results "The Company announces that it has signed a letter of intent for the licence to manufacture and sell its second generation retractable safety syringes." 19 January 2005 - Letter of Intent Signed "Although no formal contract has been signed and no licence fee payments have been received ...the Company received written confirmation ...from the prospective licensing partner re-affirming its intention to enter into a legally-binding contract ...Your board believes that this development represents a significant step forward. 113 22 August 2005 - Interim Results Volvere does not regard confirmatory letters of intent as significant steps forward. The facts are that the Company has reported no sales and no licensing or distribution contracts since 2003. In the last five years, Anthony Fletcher has been Finance Director, Chief Operating Officer and Chairman of the company. During that period 4 he has been paid salary, fees and benefits of £649,481. In light of the Company's financial performance, Volvere considers that such amounts are excessive and that he should be removed from the Board. Laurence Rostron has been a Board member since 8 July 2003. ' Retained losses as of 30/O6/2005 = O1/01'2004 to 30/06/2005 ' Anthony Fletcher, EGM Circular `' Year to December 2000: £161,325; 2001: £185,553; 2002: £157,707; 2003: £47,750; 2004: £97,146 Volvere believes that when a company is losing money and the directors are being paid out of capital that is substantially not their own, there must be convincing evidence of value being delivered for the directors to be supported. Volvere believes that the members of the current Board have failed to deliver value for NMT shareholders, and that they should be replaced at the EGM of the Company to be held on 14 September 2005. Who is Volvere plc`' Founded to invest in turnaround situations. The directors and their associated companies own 38.6 per cent.5 of the issued ordinary share capital of Volvere. One operating subsidiary: Vectra Group Limited, which was acquired in May 2003. Share price has risen 75 per cent.' since it was admitted to AIM in December 2002. At 31 December 2004, Volvere had net assets of £3.84 million including cash of £3 million. As at 25 August 2005, Volvere, through its nominee, holds 2,269,024 NMT ordinary shares representing 26.04 per cent. of the issued ordinary share capital of NMT. Who are the proposed directors`' Lord Kalms of Edgware Lord Kalms is Chairman of Volvere. He created the Dixons Group from a one store family business into one of Europe's leading retailers with a current market value of £2.9 billion, in a career spanning more than half a centurv. He is now Life President of the Dixons Group having stood down as Chairman of Dixons in 2002. Awarded a Knighthood in 1996 in recognition of his services to the electrical retailing industry, and awarded a Life Peerage in June 2004. In addition to his previous responsibilities as Chairman of Dixons Group, a selection of his other posts have included: • Chairman of King's College Healthcare NHS Trust • None-executive Director of British Gas plc • Governor of the National Institute of Economic and Social Research • Director of Business for Sterling Jonathan Lander Jonathan is Volvere's CEO. He founded Volvere in 2002. Jonathan is also the founder of Dawnay, Day Lander Limited ("DDL"), a venture capital firm that invests in technology companies. Jonathan has 15 years experience in the City, including 4 years with the Nomura and West LB Panmure Technology Groups where he was involved with many biotechnology companies including medical device companies. ` Volvere Annual Report 2004. Directrors' interests in Volvere ordinary shares: Lord Kalms 250,000; Neil Ashley 250,000; David Buchler 28,985; Richard Kalms 250,000; Jonathan Lander 100.000: Nick Lander 25,000; Dawnay, Day Lander Limtied 250,000; Ashley Grandchildren's 2003 settlement 250,000 ~' AIM listing price: 100p. Price at 23:'08 2005: 175p D D D Nicholas Lander Nick is Volvere's Chief Financial Officer and Chief Operating Officer. Nick qualified as a Chartered Accountant with Pricewaterhouse Coopers in Glasgow in 1990. He was formerly Corporate Development Director of Clyde Blowers plc and was involved in taking the company private in 1999. Prior to joining Clyde, Nick spent 6 years with APV plc (now part of Invensys plc), latterly as Managing Director of a subsidiary that was the subject of a successful turnaround. He is additionally Chief Operating Officer of DDL. 'Volvere's plans for NMT I f the directors proposed by Volvere are elected to the Board of NMT, they intend to make an assessment of the viability of the current business of the Company with particular attention to the Company's order pipeline. They will do this whilst paying close attention to the cash burn associated with maintaining the status quo. Depending on the result of that analysis, they will either continue to invest in, sell or close the Company's business. They will also review any proposals currently being made in respect of NMT, including any offer for NMT by Zi Medical PLC. Shareholders should note that NMT is currently only in preliminary talks with Zi Medical PLC regarding a potential SHARE offer for the company.' Volvere does not want to close down NMT or stop initiatives that might make money for shareholders. On the contrary, where appropriate, Volvere will continue and extend the exploration of strategic options in order to seek to identify the best way in which to maximise the value of the Company's assets for shareholders, but without the associated overhead of a Board that is not a significant shareholder. Volvere therefore does not agree with Tony Fletcher's statement that removal of the existing Board would "curtail that activity."8 Shareholders can take comfort from the fact that as NMT's largest shareholder, Volvere will act in the interests of shareholders. Yours sincerely, Lord Kalms Chairman Volvere plc VOTE NOW Sign and return your BLUE proxy card without delay Yolvere plc: Registered in England No. 04478674 Registered address: 9-11 Grosvenor Gardens, London SWI W OBD The persons responsible for this document are the directors of' Volvere plc. ' Zi Medical PLC announcement 23/08/2005 " EGM Circular Printed by CGI (Europe) Ltd pc
25october1969: SRSM Firstly it is no secret that I am all of the above names, a long story which I did post on TMF some time ago. Secondly, I still own over 3% Thirdly I have not had any approaches from NMT management or Volvere. I posted on TMF a week or so ago and basically said that Volvere had been good for the share price. I presume that with respect to NMT, the main interest of everyone who reads this board is for the share price to go up. Whether you love them or hate them, the share price has risen from around 57 to over 70 since the involvement of Volvere and this fact alone has to be welcomed. It is a fact that the management of NMT have failed to deliver insofar as the bottom line is concerned. The latest Accounts show turnover for the six months to 30 June 2005 of ZERO. For the 12 months to 31 December 2004, turnover was ZERO. At 30 June 2004 cash was £9.7m, at 30 June 2005 cash was £6.5m, a fall of over 30%. (I appreciate there was a provision of £2.5m in 04) I am not saying that the company has been mismanaged or that anyone else could do better. I am saying that this sorry state of affairs could not be allowed to continue unchallenged until all the cash had disappeared, Volvere have made that challenge. It is all very well if NMT produce the best syringe in the world but I am an investor not a scientist and I need revenues and profits. NMT have looked a long way from delivering that. So much for the negative views on NMT management. On the positive side, it does appear that contract negotiations are continuing better than I expected and clearly this is welcomed. Only time will tell however if they can deliver something substantial which will significantly increase shareholder value. I have no idea of the detailed intentions of Volvere apart from their clearly wishing to make a profit from their investment – a common purpose for all shareholders. They have taken a high risk strategy and I do not think it is in anyone's interests if they walk away. What will happen to the share price if they make it public knowledge that they wish to sell a 26% stake? We therefore have to live with them. Clearly the biggest concern is that they will screw the smaller shareholders – myself included. I hope however the LSE and Companies Act rules will make this difficult for them if this was their intention. Also if they were to become directors, they have a duty of care to act in the best interests of all shareholders and I would not hesitate to take whatever action was available if they did not do this. In view of the recent news with respect to the contract and the ZIM approach I think that in would be in everyone's interests for the EGM resolutions to be amended/withdrawn and for Volvere and NMT to work together to ensure that NMT shareholders get the best deal with respect to the ZIM approach. It also does not make sense to change the management team at this stage of the contract negotiations. I therefore think that Volvere should have one seat on the Board as their shareholding merits it and I suspect the more clout NMT have the better with respect to the ZIM discussions. It makes no sense for Tony Fletcher to be removed cheers Roy
pc4900074200: As I see it. The NMT share price moved up to the higher 2's for no reason. Given the circumstances of the lack of new sales for the first generation syringes [ very hard in a market that the Americans dominate ] and that the contract with Roche would expire in the first quarter of 2004. NMT have choice but to terminate production. Remember that the Roche contract have given NMT one extra year during which they have progressed with the generation II syringe. It would not have been too long before the 1st Generation syringe would have been discontinued. The other factor is that the price of the first generation syringe was exspensive. [ as with all inventions, especially given that the design of this type of syringe far exceeds any other in application on the market]. We have been told that NMT are still in discussions with several partners regarding the Second Generation syringe and the licensing of it. This IMO means that there could be, or will be, an announcement that NMT have joined with another Company to market The II gen. syringe and other products that they manufacture. Now we must take into consideration that NMT have said that Redundancies will be fazed in, during the next three months. Many options can present them-selves to NMT during that time. Which could change the position of the Company, there-by putting them in a position that not all or any of the workforce have to leave. AISI. All the 'bad news', is now built into the price of the share and the price of the share will float along around its present value. Remember that we long term'ers have been there before. [ mid 2002 To mid 2003]. Remember NMT have the Vaxess™ The NMT Safety IV Catheter. and talks are in progress about the range of Prefill Safety Needle units. Before some one cries, 'what about the court case'. That was based around The 1st Generation syringe and the design. This is old news. NMT Were fighting this and the expectations were for vindication that there were no infringements made. We go forward into 2004 with possible announcements made around the 2nd Quarter, with the share gaining strength in the coming months. IMO. My position is a strong hold and for good expectations in the months ahead. pc
Nmt Group share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180220 03:51:28